Abstract
Objectives
Galectin-3 is a member of the glycoprotein family, actively involved in various biological interactions including cell growth, cell adhesion, cell differentiation and apoptosis. The aim of this study was to analyze the expression of galectin-3 in clear cell renal carcinoma and to assess its prognostic significance.
Methods
The expression of galectin-3 was analyzed by immunohistochemistry in 149 clear cell renal carcinomas. The levels were correlated to established clinical parameters such as nuclear grade, pathological stage, lymph node, distant metastasis, and patients’ survival.
Results
In normal kidney tissue, the expression of galectin-3 was found to be uniformly present in the tubular epithelial cells. A decrease of antigen expression levels were significantly associated with higher T-stages (P < 0.02), unfavourable long-term prognosis in univariate Kaplan–Meier (P < 0.007) and multivariate Cox proportional hazard analyses (P < 0.04). Univariate analysis could demonstrate an association with tumor-specific death with decreased galectin-3 expression, whereas multivariate analysis failed to prove the aforementioned observation.
Conclusion
Our results suggest that a loss of galectin-3 expression is involved in renal carcinogenesis.
Similar content being viewed by others
References
Jemal A et al (2006) Cancer statistics 2006. CA Cancer J Clin 56(2):106–130
Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169(3):821–827
Young AN et al (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158(5):1639–1651
Nakahara S, Raz A (2006) On the role of galectins in signal transduction. Methods Enzymol 417:273–289
Califice S et al (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23(45):7527–7536
van den Brule FA et al (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89(4):361–367
Cindolo L et al (1999) Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84(1):39–43
Francois C et al (1999) Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 112(2):194–203
Merseburger AS et al (2005) Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25(3B):1901–1907
Merseburger AS et al (2006) Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma. Urologe A 45(3):323–327
Merseburger AS et al (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48(3):519–526
Kramer MW et al (2007) Tissue microarrays in clinical urology—technical considerations. Scand J Urol Nephrol 41(6):478–484
Ingrassia L et al (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13(29):3513–3527
Hahn HP et al (2004) Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 11(12):1277–1286
Rabinovich GA et al (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23(6):313–320
Castronovo V et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43–48
Choufani G et al (1999) The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86(11):2353–2363
Shimamura T et al (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8(8):2570–2575
Inohara H et al (1999) Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85(11):2475–2484
Hsu DK et al (1999) Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81(4):519–526
Lotan R et al (1994) Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56(4):474–480
Acknowledgments
The immunohistochemical experiments have been performed in the laboratory facilities of Dr. Vinata B. Lokeshwar (University of Miami, Miller School of Medicine). We greatly thank her for providing the antibody for galectin-3 and continuous support and scientific discussion throughout the course of this work.
Conflict of interest statement
Axel S. Merseburger was partly sponsored by a grant from MSD Sharp Dome. Mario W. Kramer was supported by a grant from the BMEP (Biomedical Science Exchange Program).
Author information
Authors and Affiliations
Corresponding author
Additional information
Axel S. Merseburger and Mario W. Kramer contributed equally to the manuscript.
Rights and permissions
About this article
Cite this article
Merseburger, A.S., Kramer, M.W., Hennenlotter, J. et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 26, 637–642 (2008). https://doi.org/10.1007/s00345-008-0294-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-008-0294-8